Policy / Pricing Italy leads the way on child genetic disease diagnosis PharmaphorumA scheme to hasten the diagnosis of children with genetic disorders is achieving strong results and could be a template for national health systems.Policy / PricingRare DiseaseRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum A scheme to hasten the diagnosis of children with genetic disorders is achieving strong results and could be a template for national health systems. Policy / PricingRare DiseaseRead full story Post navigation Previous: Asahi Kasei acquires German company AicurisNext: Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy Related Stories Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged pharminent May 13, 2026 Policy / Pricing EU agrees plan to tackle essential medicine shortages pharminent May 12, 2026 Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) pharminent May 12, 2026
